Free Case Review


The Strength of HHK

  • Over $35 Billion Recovered.
  • Over 70 Years Of Experience.
  • Leading The Fight Against BP.
  • Cutting Edge Courtroom Presentations.
  • No Recovery. No Fee.

Recent Victories

Brain Injury


Burn Injury


Offshore Maritime


Client Testimonials


New Orleans, LA Lawyers Investigating the Effect of Actos

Attorneys at Herman Herman & Katz are investigating claims on behalf of those who took the drug Actos to treat type II diabetes.

What is Actos?

Man holding his stomachActos is in a class of insulin-sensitizing drugs known as thiazolidinediones (TZDs) or glitazones. Actos is used to treat type II diabetes. It acts upon the insulin-sensitive genes involved in the control of glucose and lipid metabolism in muscle and the liver. As such, actos is supposed to reduce insulin resistance; increase the body’s expense of insulin-dependent glucose; decrease withdrawal or glucose from the liver; and reduce the amount of glucose, insulin, and glycated hemoglobin in the bloodstream. Actos is used in monotherapy and in combination with metformin and glimepiride. 

What is the risk involved in taking Actos?

The FDA approved Actos for the treatment of type II diabetes in 1999. From before its approval and thereafter, actos collaborated to design, research, manufacture, test, advertise, promote, market, sell, and distribute actos in the united states.

In June 2011, the FDA, as well as the FDA’s counterpart agencies in France and Germany, took action against actos because of revelations of increased incidents of bladder cancer in patients taking actos. The French agency ordered actos withdraw from the market. The german agency advised doctors not to put new patients on actos. The FDA announced that information about an increased risk of bladder cancer will be added to Actos’ labeling. However, from 1999-2011 and the present, patients who were prescribed actos developed bladder cancer because the defendants concealed, and continue to conceal, their knowledge that actos can causes bladder cancer.

Before its approval by the FDA, drug-induced tumors were observed in rats receiving actos in levels equivalent to clinical dose. In 2005, the results of a three year study which investigated the impact in total mortality and macrovascular morbidity in actos, were released. The researchers found a statistically significant increase in the incidents of bladder cancer in patients taking actos. 

In 2010, the FDA issued a safety announcement that identified a three year liver safety study performed in regard to actos that also showed an increased incident of bladder cancer in patients taking actos. In 2011, the FDA issued another safety announcement in regard to actos in which it unequivocally stated that use of the diabetes medication actos for more than one year may be associated with an increased risk of bladder cancer. Information about this risk was ordered to be placed in the Warnings and Precautions section of the actos label.

Why should Actos manufacturers be held liable?

Actos is one of the top selling drugs for Defendants. It has been listed as one of the top ten best selling medications in the US in various years. The manufacturers of Actos either knew or should have known of the relationship between Actos and bladder cancer. However, the manufacturers chose not to inform patients, doctors, or the medical community.

If you or someone you know have been injured from the drug Actos, learn about your legal rights from an experienced Louisiana class action lawyer by calling 504-581-4892 or by filling out our free, no obligation case review form.

Herman Herman & Katz, LLC
820 O Keefe Ave
New Orleans, LA 70113
Phone: (504) 581-4892

Copyright ©2017 Herman Herman & Katz, L.L.C.

Leave a Reply

Your email address will not be published. Required fields are marked *